PathAI, a Boston, MA-based global provider of artificial intelligence-powered technology for pathology, raised $60m in Series B funding.
The round was led by new investor General Atlantic, with participation from General Catalyst and other existing investors. In conjunction with the funding, General Atlantic Managing Director Dr. Michelle Dipp will be joining PathAI’s board of directors.
The company intends to use the funds to:
– enhance offerings to existing partners,
– drive continuous improvement of its flagship pathology research platform,
– meet market demands, and
– accelerate research and development into new tools and medical devices.
Led by co-founder and Chief Executive Officer Dr. Andy Beck, PathAI is a provider of AI-powered research tools and services for pathology. Its platform aims to substantially improve the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
The company works with life sciences companies and researchers to advance precision medicine.